Z. Chen et al. / Tetrahedron 70 (2014) 2237e2245
2243
159.5, 141.5, 141.3, 133.7, 133.3, 130.6, 129.9, 119.3, 117.3, 26.7, 26.6;
(br s, 1H), 7.81 (br s, 1H), 7.23e7.12 (m, 4H), 6.81e6.71 (m, 6H); 13
C
MS (ESI): m/z 164.1 [MþHþ].
NMR (75 MHz, DMSO-d6)
d
167.8, 160.6, 149.5, 148.8, 129.0, 128.8,
119.5, 118.7, 112.4, 112.2; MS (ESI): m/z 137.1 [MþHþ].
4.3.11. 4-Formamidobenzoic acid (Table 2, entry 11). The presence of
two rotamers (ratio 3:1) was observed in the NMR spectra. Yellow
4.3.18. N0-(2,4-Dinitrophenyl)formohydrazide
(Table
2,
entry
solid. Mp: 258.1e261.3 ꢀC; 1H NMR (300 MHz, DMSO-d6)
d
12.76 (br
18). The presence of two rotamers (ratio 4:1) was observed in the
s, 2H), 10.51 (br s, 1H), 10.45 (d, J¼11.4 Hz, 1H), 8.95 (d, J¼10.8 Hz,
NMR spectra. Yellow solid. Mp: 196.8e198.0 ꢀC; 1H NMR (300 MHz,
1H), 8.34 (br s, 1H), 7.96e7.84 (m, 4H), 7.74e7.66 (m, 2H), 7.29
DMSO-d6)
d
10.46 (br s, 3H), 10.18 (br s, 2H), 8.85 (d, J¼2.4 Hz, 1H),
(d, J¼7.2 Hz, 2H); 13C NMR (75 MHz, DMSO-d6)
d
166.9, 162.7, 160.2,
8.40 (dd, J¼9.6, 2.4 Hz, 1H), 8.33 (dd, J¼9.3, 2.4 Hz, 1H), 8.25 (s, 1H),
142.7, 142.2, 131.0, 130.6, 125.6, 125.5, 118.6, 116.4; MS (ESI): m/z
8.13 (s, 1H), 7.36 (d, J¼9.6 Hz, 1H), 7.23 (d, J¼9.6 Hz, 1H); 13C NMR
166.0 [MþHþ].
(75 MHz, DMSO-d6)
d 160.5, 148.1, 136.8, 130.2, 129.8, 123.2, 115.5;
MS (ESI): m/z 227.0 [MþHþ].
4.3.12. Methyl 2-formamidobenzoate (Table 2, entry 12). The pres-
ence of two rotamers (ratio 5:1) was observed in the NMR spectra.
4.3.19. 1H-Benzo[d]imidazole (Table 2, entry 19). White solid. Mp:
182.0e183.3 ꢀC; IR (KBr): 3114, 3000, 1478, 1460, 1275, 1255, 752,
White solid. Mp: 49.1e50.5 ꢀC; 1H NMR (300 MHz, CDCl3)
d 10.98
777 cmꢂ1 1H NMR (300 MHz, DMSO-d6)
; d 12.44 (br s, 1H), 8.23
(br s, 1H), 10.45 (br s, 1H), 8.94 (d, J¼10.8 Hz, 1H), 8.70 (d, J¼8.1 Hz,
1H), 8.50 (br s, 1H), 8.03 (d, J¼7.8 Hz, 2H), 7.54 (t, J¼7.8 Hz, 2H), 7.36
(d, J¼7.8 Hz, 1H), 7.11 (t, J¼7.8 Hz, 2H), 3.92 (s, 6H); 13C NMR
(br s, 1H), 7.61e7.58 (m, 2H), 7.20e7.17 (m, 2H); 13C NMR (75 MHz,
CDCl3)
d
142.0, 138.2, 121.8, 115.4; MS (ESI): m/z 119.1 [MþHþ].
(75 MHz, CDCl3) d 168.6,161.4, 159.6,140.5,134.8,131.0, 123.2,121.2,
115.2, 52.5; MS (ESI): m/z 180.1 [MþHþ].
4.3.20. N-Benzylformamide (Table 2, entry 20). The presence of two
rotamers (ratio 5:1) was observed in the NMR spectra. White solid.
Mp: 60.4e62.8 ꢀC; IR (KBr): 1650 (C]O) cmꢂ1; 1H NMR (300 MHz,
4.3.13. N-(4-Hydroxyphenyl)formamide (Table 2, entry 13). The
presence of two rotamers (ratio 3:1) was observed in the NMR
spectra. Grey solid. Mp: 135.1e137.1 ꢀC; IR (KBr): 3580, 3396, 2952,
2848, 2207, 1664, 1517, 1020, 772 cmꢂ1; 1H NMR (300 MHz, DMSO-
CDCl3) d 8.22 (br s, 2H), 7.36e7.23 (m,10H), 6.20 (br s,1H), 5.13 (br s,
1H), 4.45 (d, J¼6.0 Hz, 2H), 4.38 (d, J¼6.3 Hz, 2H); 13C NMR (75 MHz,
CDCl3)
d 165.7, 161.2, 137.6, 129.0, 128.8, 128.0, 127.8, 127.7, 127.0,
45.7, 42.2; MS (ESI): m/z 136.1 [MþHþ].
d6)
d
9.91 (br s, 1H), 9.86 (d, J¼10.5 Hz, 1H), 9.03 (br s, 1H), 8.50
(d, J¼11.1 Hz, 1H), 8.16 (d, J¼1.5 Hz, 1H), 8.14 (br s, 1H), 7.38
4.3.21. N-Butylformamide (Table 2, entry 21). Colourless oil. 1H
(d, J¼9.0 Hz, 2H), 6.98 (d, J¼8.7 Hz, 2H), 6.73e6.69 (m, 2H),
6.51e6.43 (m, 2H); 13C NMR (75 MHz, DMSO-d6)
d 163.2, 162.7,
NMR (300 MHz, CDCl3)
d 8.44 (br s, 1H), 7.41 (br s, 1H), 2.85
158.9,154.3,153.6,148.7, 130.1, 129.7, 120.8, 120.2, 115.9, 115.7, 115.6,
(t, J¼7.5 Hz, 2H), 1.66e1.56 (m, 2H), 1.40e1.28 (m, 2H), 0.89
115.2; MS (ESI): m/z 138.0 [MþHþ].
(t, J¼7.5 Hz, 3H); 13C NMR (75 MHz, CDCl3)
13.6; MS (ESI): m/z 102.1 [MþHþ].
d 169.2, 39.3, 29.7, 19.9,
4.3.14. N-(Naphthalen-1-yl)formamide (Table 2, entry 14). The
presenceoftworotamers(ratio5:2)wasobservedintheNMRspectra.
White solid. Mp: 125.8e127.3 ꢀC; IR (KBr): 3226, 1578, 1538, 1504,
4.3.22. N-Formylpiperidine (Table 2, entry 22). Colourless oil. IR
(KBr): 2940, 2860, 1588, 1441, 1400, 1369, 1348, 1328, 1280,
1396, 1270, 790 cmꢂ1; 1H NMR (300 MHz, CDCl3)
d
9.10 (d, J¼9.6 Hz,
1118 cmꢂ1 1H NMR (300 MHz, CDCl3)
; d 7.95 (br s, 1H), 3.42 (t,
1H), 8.64 (d, J¼11.1 Hz,1H), 8.60 (br s,1H), 8.05 (d, J¼7.8 Hz,1H), 7.99
(d, J¼7.5 Hz, 1H), 7.91e7.85 (m, 2H), 7.79 (d, J¼8.4 Hz, 1H), 7.71
(d, J¼8.1 Hz, 1H), 7.62e7.43 (m, 3H), 7.31 (d, J¼7.2 Hz, 1H); 13C NMR
J¼5.5 Hz, 2H), 3.36 (t, J¼5.5 Hz, 2H), 1.68e1.58 (m, 2H), 1.58e1.44
(m, 4H); 13C NMR (75 MHz, CDCl3)
d 160.9, 46.9, 40.7, 26.6, 25.1,
24.7; MS (ESI): m/z 114.1 [MþHþ].
(75 MHz, CDCl3) d 164.5, 160.0, 134.3, 134.1, 132.4, 131.1, 128.9, 128.6,
127.8, 127.1, 127.0, 126.9, 126.9, 126.3, 126.2, 125.8, 125.6, 121.5, 121.0,
4.3.23. N-Benzyl-N-(o-tolyl)formamide (Table 2, entry 23). The
120.6, 119.0; MS (ESI): m/z 172.1 [MþHþ].
presence of two rotamers (ratio 8:1) was observed in the NMR
spectra. Colourless oil; 1H NMR (300 MHz, CDCl3)
d
8.55 (br s, 1H),
8.16 (br s,1H), 7.31e7.10 (m,17H), 6.89e6.86 (m, 3H), 4.82 (br s, 2H),
2.09 (s, 3H), 2.01 (s, 3H); 13C NMR (75 MHz, CDCl3)
162.9, 161.8,
4.3.15. N-(Pyridin-2-yl)formamide (Table 2, entry 15). The presence
of two rotamers (ratio 1:1) was observed in the NMR spectra. Yel-
low solid. Mp: 34.1e36.5 ꢀC; IR (KBr): 3197, 2852, 1691, 1595, 1433,
d
139.0,136.4,136.1, 131.4, 131.1,129.2,129.1, 128.8,128.6,128.5,128.4,
128.3, 127.8, 127.7, 126.9, 126.8, 54.7, 49.5, 17.8, 17.7; MS (ESI): m/z
226.1 [MþHþ].
1303, 778, 517 cmꢂ1 1H NMR (300 MHz, DMSO-d6)
; d 10.60 (br s,
1H), 9.28 (d, J¼10.2 Hz, 1H), 8.32 (br s, 1H), 8.24 (d, J¼3.9 Hz, 1H),
8.06 (d, J¼8.1 Hz, 1H), 7.81e7.71 (m, 1H), 7.37e7.22 (m, 1H),
7.14e7.06 (m, 2H), 6.92 (d, J¼8.1 Hz, 1H); 13C NMR (75 MHz, DMSO-
4.3.24. N,N-Diphenylformamide (Table 2, entry 24). White solid.
Mp: 68.2e70.0 ꢀC; IR (KBr): 3062, 2918, 1659, 1595, 1496, 1446,
d6) d 169.2, 162.2, 160.4, 151.6, 148.1, 138.8, 138.4, 128.3, 127.3, 119.3,
113.8, 111.2; MS (ESI): m/z 123.0 [MþHþ].
1230 cmꢂ1
;
1H NMR (300 MHz, CDCl3)
d
8.68 (s, 1H), 7.45e7.37
(m, 4H), 7.35e7.24 (m, 4H), 7.20e7.15 (m, 2H); 13C NMR (75 MHz,
4.3.16. Methyl 3-formamido-4-methylthiophene-2-carboxylate
(Table 2, entry 16). The presence of two rotamers (ratio 4:3) was
observed in the NMR spectra. Yellow solid. Mp: 127.0e129.7 ꢀC; 1H
CDCl3)
d 161.9, 141.9, 139.7, 129.8, 129.3, 127.2, 127.0, 126.3, 125.2;
MS (ESI): m/z 198.1 [MþHþ].
NMR (300 MHz, CDCl3)
d 9.22 (br s, 1H), 8.85 (br s, 1H), 8.77 (d,
4.3.25. N-Formyl imidazole (Table 2, entry 25). Colourless oil. 1H
J¼11.1 Hz, 1H), 8.82 (d, J¼8.4 Hz, 1H), 8.37 (br s, 1H), 7.18 (d,
J¼10.2 Hz, 1H), 3.88 (s, 6H), 2.34 (s, 3H), 2.24 (s, 3H); 13C NMR
NMR (300 MHz, CDCl3)
d
8.72 (s, 1H), 8.02 (m, 1H), 7.17 (d, J¼0.9 Hz,
2H); 13C NMR (75 MHz, CDCl3)
d 169.0, 157.7, 134.2, 120.6; MS (ESI):
(75 MHz, CDCl3) d 163.6,161.9, 158.8,141.4,135.9, 130.6,129.4,127.9,
m/z 97.0 [MþHþ].
52.3, 52.2, 16.7, 16.0; MS (ESI): m/z 200.0 [MþHþ].
4.3.17. N0-Phenylformohydrazide (Table 2, entry 17). The presence of
4.3.26. (S)-N-Formyl-ethyl-phenylalaninate (Table 2, entry 28).
Colourless oil. 98% ee. 1H NMR (300 MHz, CDCl3)
8.16 (br s, 1H),
7.32e7.22 (m, 3H), 7.17e7.11 (m, 2H), 6.24 (br s, 1H), 4.98e4.91
(m, 1H), 4.19 (q, J¼7.2 Hz, 2H), 3.15 (dd, J¼5.7, 2.7 Hz, 2H), 1.26
d
two rotamers (ratio 5:3) was observed in the NMR spectra. Yellow
solid. Mp: 121.0e123.6 ꢀC; 1H NMR (300 MHz, DMSO-d6)
d
9.73
(br s, 1H), 9.45 (d, J¼10.8 Hz, 1H), 8.12 (br s, 1H), 8.08 (br s, 1H), 8.02